PHM Protech Home Medical Corp

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company focused on
rolling-up annuity-based healthcare service companies in the US and Canada,
today announced it has released significantly improved year-over-year audited
financial statements showing a profitable and cash flow positive fiscal year
ended September 30, 2013. It also released impressive revenue growth results for
its unaudited report for first quarter of fiscal 2014 ended December 31, 2013. 


In conjunction with the results, PHM's management provided details behind the
impressive triple digit revenue growth and its continued strategy to acquire
earnings accretive companies with strong patient relationships providing
additional revenue opportunities. 


PHM will broadcast an earnings call and webcast on Wenesday, January 29, 2014 at
12:00 pm ET to review and discuss the first fiscal quarter of 2014 and the
fiscal year end results for 2013. 


To listen, please visit PHM's investor website at:
www.phmhometesting.com/investor/Q1_2014_Conferencecall


Q1 2014 Financial Highlights

Triple Digit Revenue Quarterly Revenue Growth and Significant Increase in
EBITDA, Net Profit and Cash Flow




--  120% increase in quarterly revenues; Increased revenue from $1,040,000
    to $2,363,000 from the same quarter a year ago. 
    
--  Quarterly EBITDA before patient acquisition costs of $285,000; 
    
--  Quarterly net profit before stock based compensation of $140,000; 
    
--  Generated positive cash flow of $5,050,000, an increase of $4,850,000 in
    cash flow compared to the same quarter a year ago. 
    
--  Working Capital increased by $9,000,000 compared to the same quarter a
    year ago. 



"The results for the first quarter of fiscal 2014 highlight our significant
revenue growth," said Mr. Bob Kusher, CEO of PHM. "In FY 2013, we accelerated
profit growth and with this most recent quarter, we generated strong, triple
digit revenue growth as well. We continue to focus our energies on cross selling
and acquiring quality companies that can increase our patient database. The
financial results from this quarter reaffirms the increasing value of PHM to its
shareholders."


Full Year (Ended September 2013) Audited 2013 Financial Highlights



--  Improvement of 42% of Adjusted EBITDA before patient acquisition
    costs(1) (operating profit) from FY 2012. 
    
--  PHM generated $297,000 in operating profit for FY 2013, compared to a
    loss of ($585,000) for FY2012, a swing of over $850,000. 
    
--  Generated Adjusted EBITDA to $830,000 in FY2013 from ($150,000) in
    FY2012, a swing of over $980,000. 
    
--  Swung to positive EPS, an increase of $0.011 per share(2) 



"This was our first full year reporting profits and cash flow," said Mr. Bob
Kusher, CEO of PHM. "We were able to optimize our operations to produce positive
cash flow and growing profits. In the first 4 months of our FY2014, we have
already increased revenues significantly through acquisitions, improving EPS and
providing us a platform for increased revenue and profit through our cross
selling efforts." 


For complete financial results, please see PHM's filings at www.sedar.com.

(1) Operational Profitability is defined as Adjusted EBITDA before patient
acquisition costs. In calculating Adjusted EBITDA before patient acquisition
costs certain items are excluded from net loss including interest, taxes,
amortization, non-cash stock-based compensation, and patient acquisition costs.
Please refer to the "Non-IFRS Measures" section of PHM's MD&A for further
discussion on these operational measures at:

http://www.phmhometesting.com/investor/public/dl/2013_Q1_MD&A.pdf

(2) EPS does not include an IFRS Fair Value of Options, Warrants and Derivative
Financial Expenses (Note 13 on the financial statements). 


About PHM 

PHM is a healthcare services company focused on providing in-home testing for
patients on blood thinner medications such as Coumadin(R) or warfarin. Medicare
recently expanded reimbursement for in-home patient self testing (PST) of blood
coagulation levels. PHM has a unique value proposition to cardiology groups that
manage patients on blood thinners, focusing on systemization to enroll patients
in PST. This unique, systemized approach creates an opportunity for physician
groups to operate more efficiently, increasing revenue to their clinic while
providing a higher standard of care for patients.


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, dependence on few payors, possible new drug discoveries, a
novel business model, dependence on key suppliers, granting of permits and
licenses in a highly regulated business, competition, low profit market segments
as well as general economic, market and business conditions, and could differ
materially from what is currently expected. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Patient Home Monitoring
Michael Dalsin
Chairman
Managing Director, Stanmore Capital Partners, Inc
(323) 253-3055
www.phmhometesting.com

Patient Home Monitoring Corp. (TSXV:PHM)
Historical Stock Chart
From Sep 2024 to Oct 2024

Patient Home Monitoring Corp. (TSXV:PHM)
Historical Stock Chart
From Oct 2023 to Oct 2024